Investors
FAQ
What is AXIM Biotechnologies, Inc.'s stock symbol?
Our stock is traded on the OTCQB under the symbol AXIM.
How can I buy AXIM shares?
You can buy AXIM shares through a broker, just as you would other securities.
How can I keep up to date with latest developments at AXIM?
You can register to receive updates announced by AXIM by submitting your email address in Email Alerts on the Investor Relations section of our website.
When was AXIM Biotechnologies, Inc. incorporated?
2010
When did AXIM Biotechnologies, Inc. become a public company?
March 2014
Where is AXIM Biotechnologies, Inc. located?
6191 Cornerstone Court, E., Suite 114,
San Diego, CA 92121
When is AXIM Biotechnologies, Inc.'s fiscal year end?
December 31st
Who is AXIM Biotechnologies, Inc.'s transfer agent?
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com
Who is AXIM Biotechnologies, Inc.'s independent auditor?
RBSM LLP
805 Third Avenue
Suite 902
New York, NY 10022
T: 212-868-3669
www.rbsmllp.com
Who is AXIM Biotechnologies, Inc.'s outside legal counsel?
Phillip E. Koehnke, APC
PO Box 235472
Encinitas, CA 92024
T: 858-229-8116
pek@peklaw.com
Email Alerts
Stay informed and receive company updates straight to your inbox
Recent News
AXIM® Biotechnologies’ Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations
SAN DIEGO – March 24, 2021 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that the Company’s manufacturing partner,...
AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has successfully...
AXIM® Biotechnologies Begins Clinical Trials of its ImmunoPass Rapid Diagnostic Test with Vaccine Recipients
SAN DIEGO – February 3, 2021 – AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announces initiation of clinical trials for ImmunoPass, the...
